Pink SheetAI And FDA: A Risk-Based Approach And New Industry User Fees? The US Food and Drug Administration likely will need a risk-based approach to reviewing the artificial intelligence aspects of drug applic
ScripThe Pros And Cons Of Flying Solo With Ex-US Launches There is plenty of money to be made in the international markets for US biotechs, but deciding to go it alone or find a partner abroad remains a tr